FGFR2 and neoplasm: These very disappointing results have been mainly due to great intratumor heterogeneity for FGFR2 amplification—the FGFR2 status evaluated on archival tumor tissue may not reflect the molecular status of metastatic tumor at study screening—and to poor concordance between gene amplification and receptor expression.